Federal Healthcare Fraud and Illegal Prescribing Charges: Intent, Medical Necessity, and Defense Strategies
Missouri Doctor Indicted on 38 Federal Counts for Healthcare Fraud and Illegal Prescribing of Controlled Substances
On April 8, 2026, a federal grand jury in the Eastern District of Missouri returned a 38-count indictment against Dr. Jonathan Wayne Morris, the owner of Columbia Urgent Care in Columbia, Missouri. The charges include 23 counts of healthcare fraud under 18 U.S.C. § 1347 and 15 counts of illegal prescribing of controlled substances under 21 U.S.C. § 841(a)(1). The indictment also includes forfeiture allegations under 21 U.S.C. § 853.
An indictment is not evidence. It reflects the government's theory, advanced through a grand jury process where no defense counsel is present and no cross-examination occurs. Understanding the government's theories and their weaknesses is essential for any physician facing a similar investigation.
This case illustrates how federal prosecutors combine healthcare fraud and controlled substances charges into a single indictment to maximize sentencing exposure. It also shows DOJ's willingness to recharacterize supervision gaps and billing practices as intentional fraud. For healthcare providers, the critical question is not what the government alleges but what it can prove, particularly on the element of criminal intent. Defendants in these cases need trial counsel who understand the medicine, the billing regulations, and the criminal statutes, and who have the courtroom experience to hold the government to its burden at every stage from investigation through verdict.
The Morris indictment reflects a broader federal enforcement trend. DOJ's 2025 National Health Care Fraud Takedown charged 324 defendants and identified controlled substances diversion as a priority enforcement category alongside healthcare fraud. The DOJ Fraud Section's 2025 Year in Review confirmed that cases combining billing fraud with controlled substances violations remain a core focus of the Healthcare Fraud Unit.
The Government's Legal Theories
The Morris indictment rests on two distinct but interconnected sets of charges. Each set targets a different federal statute with different elements of proof. But the factual allegations overlap in ways that create compounding exposure for the defendant.
Healthcare Fraud: Billing for Services Not Rendered by the Named Provider
Counts 1 through 18 and 34 through 38 charge healthcare fraud under 18 U.S.C. § 1347. The government's theory is that Morris caused claims to be submitted to Medicare and Missouri Medicaid listing him as the performing provider for medical services actually performed by assistant physicians. APs are medical school graduates who have not entered a residency program. Under Missouri law, APs must practice under the training and supervision of a fully licensed physician.
The government alleges Morris did not provide that training or supervision. Instead, he let the APs train each other. He frequently left the clinic to travel domestically and internationally and to work at a separate clinic in St. Louis. During those absences, no supervising physician was on site at Columbia Urgent Care. Yet claims continued to be submitted under Morris's name.
The fraud theory turns on a specific factual assertion: when services are performed by an AP but billed under a licensed physician's name, the claim falsely represents who provided the service. But this theory has vulnerabilities. Medicare permits billing under a supervising physician's name for services furnished by certain auxiliary personnel under the "incident to" rules at 42 C.F.R. § 410.26, which require, among other conditions, direct physician supervision. Missouri's collaborative practice arrangement for assistant physicians under Mo. Rev. Stat. § 334.036 imposes separate state-level supervision requirements. The interplay between federal billing rules and state scope-of-practice laws is complex. Providers and billing staff frequently misunderstand which services may be billed under a supervising physician's NPI and which must be billed under the rendering provider's own credentials. That confusion does not constitute criminal fraud. The government must prove the defendant knew the billing was false, not merely that the billing was incorrect.
The Eastern District of Missouri prosecuted a similar case in 2023 involving another urgent care operator who billed for services performed by unsupervised APs. That case resulted in a conviction and a five-year federal prison sentence. But the existence of a prior prosecution does not establish guilt in a subsequent case. Each defendant is entitled to hold the government to its burden of proof on every element, including the critical element of intent.
Illegal Prescribing of Controlled Substances: These Are Not Opioid Charges
Counts 19 through 33 charge illegal prescribing under 21 U.S.C. § 841(a)(1). The government alleges that Morris issued controlled substance prescriptions outside the usual course of professional practice and for no legitimate medical purpose.
This indictment is not an opioid case. That matters.
Of the 15 controlled substance counts, seven involve dextroamphetamine-amphetamine (Adderall), a Schedule II stimulant. Two involve clonazepam (Klonopin), a Schedule IV benzodiazepine. Three involve hydrocodone-acetaminophen at a 10-325 milligram combination dose, which is the lowest standard formulation of that opioid. One involves alprazolam (Xanax). One involves zolpidem tartrate (Ambien), a Schedule IV sedative. One involves lorazepam (Ativan). The drugs span Schedule II through IV classifications, but the dominant thread is stimulants and benzodiazepines, not high-dose opioids.
This distinction creates specific defense opportunities on the prescribing counts.
Federal juries have heard years of media coverage about the opioid crisis. Prosecutors in opioid diversion cases benefit from that context. High-dose oxycodone prescriptions, fentanyl patches, and large-quantity opioid scripts carry an inherent aura of danger that helps the government prove its case. The substances charged here do not carry the same weight. Adderall is one of the most commonly prescribed medications in the United States for ADHD. Benzodiazepines like Klonopin and Xanax are widely prescribed for anxiety disorders, panic disorders, and seizure conditions. Ambien is a standard sleep medication. Low-dose hydrocodone combination products are routinely prescribed for moderate pain in primary care and urgent care settings.
These are medications with broad and common medical indications. That opens the door to medical necessity defenses unavailable in high-dose opioid cases.
The Medical Necessity Opening
In an opioid diversion prosecution, the government often points to objective markers of illegitimacy: quantities far exceeding therapeutic norms, prescriptions written without any clinical evaluation, patients traveling long distances to obtain drugs they could get locally, and patients paying cash to avoid insurance scrutiny. Those markers are harder to establish when the substances at issue are commonly prescribed stimulants and benzodiazepines at standard therapeutic doses.
A patient who receives a 30-day supply of 60 tablets of dextroamphetamine-amphetamine 20 MG is receiving a standard ADHD prescription. A patient who receives 30 tablets of clonazepam 1 MG is receiving a standard prescription for anxiety or seizure management. A patient who receives 21 tablets of hydrocodone-acetaminophen 10-325 for a six-day supply is receiving a short-course pain prescription entirely consistent with primary care practice.
The government must prove that each of these prescriptions lacked any legitimate medical purpose. Not that the prescribing was suboptimal. Not that the documentation was inadequate. Not that a different physician might have made a different clinical decision. The government must prove the prescription served no medical purpose at all.
That is a high bar for medications this common. Defense counsel can retain clinical experts in primary care, psychiatry, and pain management to demonstrate that the doses, quantities, and drug selections in the charged prescriptions fell within the range of accepted clinical practice for the conditions these medications treat. If even one legitimate medical purpose supported the prescription, the government's theory on that count fails.
How the Government Will Try to Prove "No Legitimate Medical Purpose"
Standard-dose prescriptions of common medications present a defense opening that experienced counsel can exploit. The indictment addresses this by shifting the jury's attention from the drugs to the circumstances surrounding the prescriptions. The most specific factual allegations on the prescribing counts target the recipients' substance use histories.
The indictment alleges that Morris prescribed controlled substances to individuals he knew had substance use disorders and that he knew issuing those prescriptions would compromise the recipients' mental and physical wellbeing. It identifies specific recipients by initials and describes their substance use histories in detail. For example, the indictment alleges that Morris prescribed dextroamphetamine-amphetamine and lorazepam to one recipient (H.G.) approximately 16 days after Morris himself texted friends that this individual needed inpatient rehabilitation for alcohol use. It alleges Morris prescribed diazepam to another recipient (E.K.) with whom he had sexual interactions and used cocaine on multiple occasions. It alleges he prescribed dextroamphetamine-amphetamine and diazepam to a third recipient (B.S.) whom Morris knew had a substance use problem and with whom he had a sexual relationship.
The government will prove these allegations through two primary evidence categories. First, medical records and pharmacy dispensing records that document the prescriptions, the dates, the quantities, and any clinical notes associated with the encounters. Second, testimony from the recipients themselves and from individuals who observed the relationships between Morris and the recipients. The indictment also references text messages, which the government will use to establish that Morris had contemporaneous knowledge of the recipients' substance use issues at the time he prescribed to them.
This evidence is designed to strip away any medical-necessity argument on a prescription-by-prescription basis. The government's theory is that a physician who knows a patient has a substance use disorder and prescribes controlled substances to that patient without a clinical evaluation, without a treatment plan addressing the substance use, and while simultaneously using illicit drugs with the patient, is not exercising clinical judgment. The government will argue the prescriptions were tools of personal relationships, not acts of medicine.
But this theory has limits. A substance use disorder does not disqualify a patient from receiving controlled substance prescriptions. Patients with histories of substance use may have co-occurring conditions that require treatment with controlled substances, including ADHD, anxiety disorders, seizure disorders, and acute pain. A physician who evaluates the clinical picture, weighs the risks, and prescribes with awareness of the patient's substance use history is exercising clinical judgment. The government must prove the physician prescribed with no legitimate medical purpose, not merely that the prescribing involved elevated risk. Defense counsel can retain addiction medicine specialists and psychiatrists to testify that prescribing controlled substances to patients with substance use histories is clinically appropriate in specific circumstances and that the prescriptions at issue were consistent with accepted practice for the conditions being treated.
The indictment describes several additional categories of allegedly illegal prescribing: prescribing to friends and associates without medical evaluations, prescribing in connection with sexual relationships, and accepting cash payments for prescriptions.
But an indictment tells only the government's side. Since the Supreme Court's decision in Ruan v. United States, 597 U.S. 450 (2022), the government must prove the physician subjectively knew or intended that the prescribing was not authorized. That requires proof of what the physician was thinking, not proof that the prescribing deviated from best practices.
The existence of a personal relationship between a physician and a patient does not, standing alone, render a prescription illegitimate. Physicians prescribe to friends and family members routinely. The question is whether the physician made a clinical judgment about medical need or whether the prescription was entirely divorced from any medical purpose. That distinction matters. Negligent or even reckless prescribing is not the same as knowingly criminal prescribing. The government must prove the latter.
The Supervision Theory: Where the Government Must Prove More Than Negligence
The indictment devotes significant attention to Morris's alleged failure to supervise the APs at Columbia Urgent Care. The supervision allegations serve double duty: they support the healthcare fraud charges and the controlled substances charges simultaneously.
On the healthcare fraud side, the government alleges that Morris held himself out as the supervising physician but failed to actually supervise. He allegedly did not train the APs, let them train each other, left the clinic unsupervised for extended periods, and directed APs to falsely document in medical records that each patient was seen by Morris.
On the controlled substances side, Morris allegedly directed APs to issue controlled substance prescriptions using his name and DEA registration. Most of the APs lacked their own DEA registrations. Morris authorized these prescriptions remotely through a dual-authentication system on his phone, even when he allegedly had not seen the patients or reviewed their medical records.
But supervision failures, standing alone, are not federal crimes. The government must prove that the supervision gaps were part of a knowing scheme to defraud, not the product of poor management, understaffing, or competing professional demands. Missouri's AP framework is itself relatively unusual among states. The collaborative practice arrangement is a state-created pathway for medical school graduates who have not matched into residency programs. Physicians who participate in these arrangements operate in a regulatory gray zone where federal billing rules, state practice laws, and DEA registration requirements do not align neatly. A physician who genuinely believed the supervision structure was adequate, or who relied on a billing company to submit claims correctly, has a defense on the intent element even if the supervision fell short of regulatory requirements.
This is the critical distinction. A regulatory violation is not automatically a crime. The government must bridge the gap between negligent oversight and intentional fraud. Experienced defense counsel forces the government to prove that gap with evidence, not assumptions.
The Intent Hurdle: The Government's Highest Burden
Every count in the Morris indictment requires the government to prove that the defendant acted knowingly and willfully. This is the most important element in every healthcare fraud and controlled substances case. An indictment can allege intent in broad strokes. At trial, the government must prove it with specific evidence tied to the defendant's actual knowledge.
Intent Under the Healthcare Fraud Statute
Healthcare fraud under 18 U.S.C. § 1347 requires proof that the defendant knowingly and willfully executed, or attempted to execute, a scheme to defraud a healthcare benefit program. The government must prove more than billing errors or negligent oversight. It must prove that the defendant knew the claims were false and submitted them with the intent to defraud.
This is where defense counsel can be most effective. The Morris indictment alleges that claims listed Morris as the performing provider when APs provided the services. But the billing mechanics matter. If a billing company or office manager coded the claims, the government must connect Morris to the specific false representations on each claim. A physician who delegates billing to staff and does not know how claims are coded occupies a fundamentally different legal position than one who personally directs the submission of false claims.
The defense in these cases focuses on what the physician actually knew about the billing process. Did the physician understand that the claims listed him as the performing provider? Did the physician believe the billing complied with Missouri's collaborative practice rules? Did the physician rely on advice from billing professionals or compliance consultants? Good-faith reliance on the advice of others, while not an absolute defense, is powerful evidence that negates the "willful" element of the charge. Billing errors caused by administrative confusion, delegation to staff, or misunderstanding of complex Medicare rules do not constitute criminal fraud.
Intent Under the Controlled Substances Act: The Ruan Standard
The intent standard for physician prescribing charges shifted decisively in 2022. In Ruan v. United States, 597 U.S. 450 (2022), the Supreme Court held that the mens rea of "knowingly or intentionally" in 21 U.S.C. § 841(a)(1) applies to the "except as authorized" clause. In practice, this means the government must prove the defendant subjectively knew or intended that the prescribing conduct was not authorized under the Controlled Substances Act. The Court rejected the objective negligence standard that the Tenth and Eleventh Circuits had applied in the cases before it.
Under Ruan, it is not enough for the government to show that a physician's prescribing deviated from accepted standards. The government must prove the physician knew the prescribing was unauthorized. This is a subjective standard. It protects physicians who exercise unconventional clinical judgment or practice in ways that deviate from mainstream norms without crossing into knowing illegality.
The Ruan standard requires the government to prove the defendant's actual state of mind at the time of each prescription. Contemporaneous medical records, clinical documentation, and testimony about the physician's clinical reasoning can all support a defense that the physician believed the prescriptions served a legitimate medical purpose. In a case involving standard-dose Adderall and benzodiazepines, that defense has particular traction.
How the Government Tries to Use Dual Theories to Overcome the Intent Hurdle
The combination of healthcare fraud and controlled substances charges in a single indictment is a deliberate prosecutorial strategy. It is designed to make the intent element easier to prove on both sets of charges.
The healthcare fraud counts allege systematic false billing. If the jury credits that evidence, the government argues it shows the clinic operated outside the bounds of legitimate medical practice. The controlled substances counts allege prescribing for personal and financial motives. If the jury credits that evidence, the government argues it shows the defendant's true intent was not to provide medical care.
This creates a defense opportunity. The billing fraud counts involve relatively small dollar amounts per claim. The prescribing counts involve standard-dose medications with legitimate medical applications. Standing alone, each set of charges requires the government to prove intent through circumstantial evidence that a defense attorney can contextualize and explain. Defense counsel can highlight to the jury that the combination of charges does not strengthen the proof on any individual count. The jury must evaluate each count independently, and the evidence supporting one theory does not automatically supply intent for another.
Defense counsel can argue to the jury that evidence of personal relationships, while emotionally charged, is legally irrelevant to whether a specific billing claim was knowingly false. Text messages about a recipient's substance use may reflect poor clinical judgment but fall short of proving subjective knowledge that each prescription was unauthorized. Experienced defense counsel challenges the admissibility of cross-count evidence under Federal Rule of Evidence 403 and seeks limiting instructions that require the jury to assess each count on its own proof.
The defendant is presumed innocent. Each count must be proven independently. The government cannot substitute volume of charges for quality of proof. And at trial, defense counsel has the tools to expose that distinction count by count.
Sentencing Exposure: The Compounding Effect of Dual Theories
The sentencing exposure in this case is substantial. Healthcare fraud under 18 U.S.C. § 1347 carries a statutory maximum of 10 years per count. Illegal distribution of controlled substances under 21 U.S.C. § 841(b)(1)(C) carries a statutory maximum of 20 years for Schedule II substances such as dextroamphetamine-amphetamine. Under 21 U.S.C. § 841(b)(2), Schedule IV violations carry a statutory maximum of 5 years per count for substances like alprazolam, clonazepam, and lorazepam.
The indictment includes forfeiture allegations under 21 U.S.C. § 853, which upon conviction requires forfeiture of property constituting or derived from proceeds of the offenses, as well as property used or intended to be used to commit or facilitate the offenses. If forfeitable assets cannot be located or have been dissipated, the government may seek substitute asset forfeiture under 21 U.S.C. § 853(p).
Under the federal sentencing guidelines, the advisory range is driven by loss calculations for the healthcare fraud counts under U.S.S.G. § 2B1.1 and drug-quantity calculations for the prescribing counts under U.S.S.G. § 2D1.1. The government will seek enhancements for abuse of a position of trust under U.S.S.G. § 3B1.3 and potentially for a leadership role under U.S.S.G. § 3B1.1. These enhancements can add years to the advisory range. But the guidelines are advisory, not mandatory, and defense counsel can argue for a variance or departure based on the specific facts of the case, the defendant's personal history, and mitigating circumstances under 18 U.S.C. § 3553(a).
Key Federal Charges in the Morris Indictment
Broader Enforcement Context: Why Physicians Must Understand These Theories
The Morris indictment is part of an accelerating federal enforcement trend that combines healthcare fraud charges with controlled substances diversion charges in a single prosecution. This dual-theory approach has become a standard DOJ strategy for cases involving physician prescribing.
The 2026 enforcement landscape reflects increased coordination between DOJ, HHS-OIG, DEA, and state Medicaid fraud control units. The Morris case was investigated by the FBI, HHS-OIG, DEA, and the Missouri Attorney General's Medicaid Fraud Control Unit. That multi-agency coordination is now standard for cases where prescribing and billing allegations overlap.
The supervision theory carries particular significance for physicians who employ mid-level providers, including assistant physicians, nurse practitioners, and physician assistants. The government increasingly treats supervision gaps as evidence of criminal intent rather than regulatory violations subject to administrative remedies. Defense counsel can highlight to juries that regulatory noncompliance and criminal fraud are different things. That distinction is a powerful defense theme.
The controlled substances charges expand the risk further. DOJ is not limiting prescribing prosecutions to opioid cases. Stimulants, benzodiazepines, and sleep medications are all being charged under 21 U.S.C. § 841. But that expansion creates defense opportunities. Non-opioid prescribing cases lack the emotional weight that opioid crisis narratives carry with juries. Medications like Adderall, Klonopin, and Ambien are prescribed millions of times per year across the country for well-established medical conditions. Defense counsel can highlight the ordinariness of these medications to a jury when challenging the government's theory that the prescribing served no medical purpose. Combined with Ruan's requirement that the government prove subjective knowledge of unauthorized conduct, a physician who prescribes commonly used medications at standard doses retains viable defenses on the intent element even in the face of a multi-count federal indictment.
Why Trial Readiness Matters in Healthcare Fraud and Controlled Substances Cases
Indictments are drafted in conference rooms. They are tested in courtrooms. The difference matters.
Every weakness in the government's case on intent becomes a trial opportunity. The government's proof in a case like this depends on cooperating witnesses, billing records, medical charts, and electronic communications. Each category is vulnerable.
Cooperating witnesses in healthcare fraud cases are billing staff, office managers, and employees who face their own criminal exposure. They cooperate to reduce their sentences. That incentive creates bias. Effective cross-examination exposes the gap between what a cooperator claims to know about the physician's intent and what the cooperator actually observed. A billing clerk who coded claims under the physician's NPI may have done so based on her own understanding of billing rules, not based on a directive from the physician. That distinction is the difference between a guilty verdict and an acquittal on the healthcare fraud counts.
Billing records are summary evidence. The government presents them in aggregate through charts and timelines designed to suggest a pattern of fraud. But aggregate data obscures individual facts. Each claim in the Morris indictment corresponds to a specific patient on a specific date. Defense counsel examines each claim against the patient's medical record, the AP's clinical notes, and the circumstances of the visit. A claim that looks fraudulent in a summary chart may reflect a legitimate clinical encounter when the underlying record is placed before the jury.
The Ruan standard makes trial essential in prescribing cases. The jury instruction requires the government to prove the physician subjectively knew the prescribing was unauthorized. That question turns on the physician's actual state of mind at the time of each prescription. Defense counsel presents that evidence live: the physician's clinical reasoning, training, understanding of prescribing norms, and belief that the prescriptions served a legitimate medical purpose. Clinical experts explain why the charged prescriptions fell within accepted practice for the conditions these medications treat. When the substances at issue are standard-dose Adderall, Klonopin, and low-dose hydrocodone, that expert testimony carries particular force.
A defense attorney who has never tried a healthcare fraud case cannot credibly threaten trial. Prosecutors know this. They calibrate plea offers and sentencing recommendations based on whether the defense will fold or fight. A trial-ready defense changes the government's calculation at every stage.
Scott Armstrong has tried sixteen federal jury trials, including nine healthcare fraud cases involving over $600 million in false claims. He directed DOJ's Appalachian Regional Prescription Opioid Strike Force and served as lead trial counsel in the Fraud Section's first use of data analytics to convict a physician for conspiring to dispense over 2 million controlled substance pills. He cross-examined cooperating witnesses, presented complex claims data to federal juries, and secured convictions in multi-week trials across the country. He now deploys that same trial skill set to defend physicians and healthcare executives facing the same charges he once prosecuted.
Frequently Asked Questions: Healthcare Fraud and Controlled Substances Charges
How does the government prove healthcare fraud when a physician supervises assistant physicians or nurse practitioners?
The government's fraud theory in supervision cases under 18 U.S.C. § 1347 targets the identity of the performing provider on the claim. When a Medicare or Medicaid claim lists a supervising physician as the rendering provider but an assistant physician or nurse practitioner performed the service, the government argues the claim contains a material misrepresentation. However, the government must prove the physician knew the claim was false and submitted it with intent to defraud. Whether AP services may be billed under a supervising physician's NPI depends on the intersection of state collaborative practice laws, CMS enrollment rules, and Medicare billing requirements. These rules are complex and vary by state. A physician who relied on billing staff to code claims correctly may lack the criminal intent that Section 1347 requires. Billing errors and negligent oversight are not federal crimes.
What is the Ruan v. United States standard for physician controlled substance prescribing prosecutions?
In Ruan v. United States, 597 U.S. 450 (2022), the Supreme Court held that the mens rea of "knowingly or intentionally" in 21 U.S.C. § 841(a)(1) applies to whether the physician's conduct was "authorized" under the Controlled Substances Act. The government must prove the physician subjectively knew or intended that the prescribing was unauthorized. An objective deviation from accepted prescribing standards, standing alone, is insufficient for conviction. This standard protects physicians who exercise unconventional clinical judgment or make honest prescribing errors. As the former Director of DOJ's Appalachian Regional Prescription Opioid Strike Force, Scott Armstrong understands how prosecutors build prescribing cases under § 841 and how the Ruan standard reshapes the defense of those cases at trial.
Can a physician face federal criminal charges for prescribing Adderall, benzodiazepines, or other non-opioid controlled substances?
21 U.S.C. § 841(a)(1) applies to all controlled substances across Schedules II through V. DOJ has brought federal criminal charges for prescribing dextroamphetamine-amphetamine (Adderall), alprazolam (Xanax), clonazepam (Klonopin), diazepam (Valium), lorazepam (Ativan), and zolpidem tartrate (Ambien). However, non-opioid prescribing cases present distinct defense opportunities. These medications have broad, well-established medical indications: ADHD, anxiety disorders, seizure conditions, and insomnia. Standard-dose prescriptions of these drugs are written millions of times per year in primary care and urgent care settings. That clinical ubiquity opens the door to medical necessity defenses that are far more difficult to mount in a high-dose opioid case. The government must prove the prescription served no legitimate medical purpose at all, which is a high burden when the charged substance is a routine therapeutic medication.
What is the difference between a regulatory violation and criminal healthcare fraud in a physician supervision case?
A regulatory violation occurs when a physician fails to comply with state collaborative practice requirements, Medicare billing rules, or DEA registration requirements. Criminal healthcare fraud under 18 U.S.C. § 1347 requires proof that the physician knowingly and willfully participated in a scheme to defraud a federal healthcare benefit program. The distinction is intent. Supervision gaps caused by understaffing, competing clinical demands, or misunderstanding of complex regulatory requirements do not constitute federal crimes. The government must prove the physician knew the billing was false and intended to deceive Medicare or Medicaid. Evidence of compliance efforts, reliance on billing professionals, and the physician's understanding of applicable state practice laws all bear directly on the intent element. This gap between regulatory noncompliance and criminal fraud is the central contested issue in most supervision-based healthcare fraud prosecutions.
How do federal prosecutors use dual healthcare fraud and controlled substance charges to increase sentencing exposure?
Federal prosecutors combine healthcare fraud charges under 18 U.S.C. § 1347 (up to 10 years per count) with illegal prescribing charges under 21 U.S.C. § 841 (up to 20 years per count for Schedule II substances) in a single indictment. This dual-theory strategy is designed to allow evidence from one set of charges to support the intent element on the other. Defense counsel can challenge the admissibility of cross-count evidence under Federal Rule of Evidence 403 and seek limiting instructions requiring the jury to evaluate each count independently. The government cannot substitute volume of charges for quality of proof. Each count must be proven beyond a reasonable doubt on its own evidence. The guidelines are advisory under United States v. Booker, 543 U.S. 220 (2005), and defense counsel can argue for a variance under 18 U.S.C. § 3553(a).
What role does a DEA registration play in a federal controlled substance prescribing prosecution?
A DEA registration authorizes a physician to prescribe controlled substances, but only for a legitimate medical purpose in the usual course of professional practice as required by 21 C.F.R. § 1306.04(a). When prescribing falls outside those boundaries, the registration does not shield the physician from criminal liability under 21 U.S.C. § 841(a)(1). In cases where a physician allows others to use the physician's DEA registration and credentials to issue prescriptions, the government alleges misuse of the registration itself. However, under Ruan v. United States, 597 U.S. 450 (2022), the government must still prove the physician subjectively knew the prescribing was unauthorized. A physician who delegated prescribing authority in good faith based on an understanding of applicable state supervision laws retains a defense on the intent element.
What is the medical necessity defense in a controlled substance prescribing case?
The medical necessity defense challenges the government's core allegation that a controlled substance prescription was issued without a legitimate medical purpose under 21 C.F.R. § 1306.04(a). Defense counsel retains clinical experts in the relevant specialty to demonstrate that the prescription was clinically indicated based on the patient's documented symptoms and the physician's clinical assessment at the time of treatment. This defense is particularly strong when the charged substances are commonly prescribed medications at standard therapeutic doses. A 30-day prescription for dextroamphetamine-amphetamine 20 MG is a standard ADHD prescription. A prescription for clonazepam 1 MG is a standard anxiety management prescription. If the defense can establish that even one legitimate medical purpose supported the prescription, the government's theory on that count fails under the "no legitimate medical purpose" element of § 841.
What experience does Armstrong & Bradylyons PLLC bring to defending healthcare fraud and controlled substance prescribing charges?
Scott Armstrong is a former Assistant Chief at DOJ's Fraud Section who tried sixteen complex federal cases, including nine healthcare fraud jury trials involving over $600 million in false claims. He served as the Director of DOJ's Appalachian Regional Prescription Opioid Strike Force, where he led the investigation and prosecution of cases involving the diversion of over 15 million controlled substance pills. At ARPO, Scott served as lead trial counsel in the Fraud Section's first-ever use of data analytics to investigate, prosecute, and convict a physician for conspiring to dispense over 2 million opioid pills. That direct experience directing controlled substance diversion prosecutions at the national level gives Scott an understanding of how the government builds these cases that few defense attorneys possess. Drew Bradylyons supervised the Healthcare Fraud Unit's South Florida Strike Force and investigated cases involving more than $1 billion in fraudulent claims.
Facing a Federal Healthcare Fraud or Controlled Substances Investigation?
Armstrong & Bradylyons PLLC defends physicians, clinic owners, and healthcare executives in federal investigations involving both healthcare fraud and controlled substances diversion. The firm provides trial-ready defense in complex dual-theory prosecutions nationwide.
